The DOI matches its Crossref record.
Pharmacokinetics and bioavailability of sodium valproate
Abstract
The pharmacokinetics of the antiepileptic drug, sodium valproate (VPA), was investigated in 6 healthy volunteers after a single intravenous dose of 400 mg, as well as a solution and enteric‐coated tablets. The bioavailability of the enteric‐coated tablets was compared with that of normal tablets in 3 of these subjects. The bioavailability studies demonstrated that the solution was rapidly and almost completely (86% to 100%) absorbed. Peak plasma levels (66 to 196 µg/ml) were reached within 0.5 to 2 hr. Tablets had comparable bioavailabilities which varied in the different persons (68% to 100%). In some subjects VPA was found in plasma only after a lag time of 1 to 4 hr and the peak plasma concentrations of 46 to 88 µg/ml developed after 3 to 7 hr. After the intravenous dose, plasma levels declined biexponentially. The pharmacokinetic parameters were computed according to the two‐compartment open model. The half‐life of the initial phase, t ½(α), could be calculated to 1.0 ± 0.86 hr (mean ± SD) and the terminal half‐life, t ½(β), varied independently of the route of administration between 8.7 and 21.5 hr (12.2 ± 3.7 hr). The distribution space of the central compartment (V 1) was 0.065 ± 0.010 Llkg, and both the apparent volume of distribution at steady‐state (Vd SS) and Vd β had similar values of 0.13 ± 0.04 L/kg and 0.14 ± 0.05 L/kg, respectively. These small volumes indicate that VPA distributes mainly into the extracellular space. The total plasma or blood clearance (Cl) ranged from 4.3 to 10.5 ml/min (7.8 ± 2.4 ml!min) and from 11.9 to 44.3 ml/min (30.1 ± 11.9), respectively. Therapeutic concentrations of VPA (80 µg/ml) revealed relatively strong plasma protein binding between 80% and 94%. The bloodlplasma concentration ratio ranged about 0.28 ± 0.06. Since the calculated hepatic extraction ratio of 0.02 is smaller than the free fraction, it is concluded that clearance of VPA is independent of liver blood flow and of the restrictive type. No measurable amounts of unchanged VPA were excreted during the 2 days of observation. Approximately 10% to 30% of a single dose was eliminated as VPA conjugates which could be hydrolyzed by 2 N HCl and β‐glucuronidase/aryl‐sulfatase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zhao, Y. H., Le, J., Abraham, M. H., Hersey, A., Eddershaw, P. J., Luscombe, C. N., Boutina, D., Beck, G., Sherborne, B., Cooper, I., et al. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1031 · Cited by 526
Prediction of Human Intestinal Absorption of Drug Compounds from Molecular Structure
Wessel, M. D., Jurs, P. C., Tolan, J. W., & Muskal, S. M. (1998) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci980029a · Cited by 365
Valproate: Past, Present, and Future
Johannessen, C. U., & Johannessen, S. I. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00249.x · Cited by 363
Mechanism of anticonvulsant action of valproate
Chapman, A., Keane, P. E., Meldrum, B. S., Simiand, J., & Vernieres, J. C. (1982) · Progress in Neurobiology · doi:10.1016/0301-0082(82)90010-7 · Cited by 337
Valproic Acid Toxicity: Overview and Management
Sztajnkrycer, M. D. (2002) · Journal of Toxicology: Clinical Toxicology · doi:10.1081/clt-120014645 · Cited by 286
Metadata
- Authors
- Klotz, U., & Antonin, K. H.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1977-06
- Volume
- 21
- Issue
- 6
- Pages
- 736-743
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1920495182
- Cited by
- 202
- References
- 0
- FWCI
- 12.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and bioavailability of sodium valproate. https://app.cochat.ai/papers/10.1002/cpt1977216736
- The paper
- Klotz, U., & Antonin, K. H. (1977). Pharmacokinetics and bioavailability of sodium valproate. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt1977216736
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.